JP2013241464A5 - - Google Patents

Download PDF

Info

Publication number
JP2013241464A5
JP2013241464A5 JP2013169146A JP2013169146A JP2013241464A5 JP 2013241464 A5 JP2013241464 A5 JP 2013241464A5 JP 2013169146 A JP2013169146 A JP 2013169146A JP 2013169146 A JP2013169146 A JP 2013169146A JP 2013241464 A5 JP2013241464 A5 JP 2013241464A5
Authority
JP
Japan
Prior art keywords
conjunctivitis
levofloxacin
eye
eye drop
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013169146A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013241464A (ja
JP5674882B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2013169146A priority Critical patent/JP5674882B2/ja
Priority claimed from JP2013169146A external-priority patent/JP5674882B2/ja
Publication of JP2013241464A publication Critical patent/JP2013241464A/ja
Publication of JP2013241464A5 publication Critical patent/JP2013241464A5/ja
Application granted granted Critical
Publication of JP5674882B2 publication Critical patent/JP5674882B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013169146A 2010-02-25 2013-08-16 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する結膜炎治療用点眼剤 Active JP5674882B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013169146A JP5674882B2 (ja) 2010-02-25 2013-08-16 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する結膜炎治療用点眼剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010040281 2010-02-25
JP2010040281 2010-02-25
JP2013169146A JP5674882B2 (ja) 2010-02-25 2013-08-16 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する結膜炎治療用点眼剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012054761A Division JP2012162532A (ja) 2010-02-25 2012-03-12 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する結膜炎治療用点眼剤

Publications (3)

Publication Number Publication Date
JP2013241464A JP2013241464A (ja) 2013-12-05
JP2013241464A5 true JP2013241464A5 (https=) 2014-01-30
JP5674882B2 JP5674882B2 (ja) 2015-02-25

Family

ID=44506417

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010280325A Active JP5600056B2 (ja) 2010-02-25 2010-12-16 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する眼感染症治療用点眼剤
JP2012054761A Pending JP2012162532A (ja) 2010-02-25 2012-03-12 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する結膜炎治療用点眼剤
JP2013169146A Active JP5674882B2 (ja) 2010-02-25 2013-08-16 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する結膜炎治療用点眼剤

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2010280325A Active JP5600056B2 (ja) 2010-02-25 2010-12-16 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する眼感染症治療用点眼剤
JP2012054761A Pending JP2012162532A (ja) 2010-02-25 2012-03-12 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する結膜炎治療用点眼剤

Country Status (16)

Country Link
US (1) US20120316158A1 (https=)
EP (1) EP2540299B1 (https=)
JP (3) JP5600056B2 (https=)
KR (2) KR20130043611A (https=)
CN (1) CN102770141A (https=)
BR (1) BR112012021247A2 (https=)
CA (1) CA2791190C (https=)
EA (1) EA201290827A1 (https=)
ES (1) ES2568647T3 (https=)
MX (1) MX349603B (https=)
MY (1) MY183483A (https=)
NZ (1) NZ602126A (https=)
PH (2) PH12016501747B1 (https=)
SG (1) SG183427A1 (https=)
TW (1) TWI488627B (https=)
WO (1) WO2011104981A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12016501747B1 (en) * 2010-02-25 2022-06-22 Daiichi Sankyo Co Ltd Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof
CN103550144B (zh) * 2013-10-25 2015-10-14 深圳朗欧医药集团有限公司 盐酸左氧氟沙星组合物注射液及其制备方法
JP6363833B2 (ja) * 2013-11-22 2018-07-25 ナノシータ株式会社 薄膜状高分子構造体
CN104606198A (zh) * 2015-01-09 2015-05-13 周元铎 盐酸左氧氟沙星在制备防治家蚕细菌性败血病药中的应用
IT201900005280A1 (it) * 2019-04-05 2020-10-05 Ntc S R L Composizione otologica

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3038722B2 (ja) 1989-06-23 2000-05-08 日本電気株式会社 接合型電界効果トランジスタ
JP3192290B2 (ja) 1993-08-04 2001-07-23 カネボウ株式会社 ポリエステル製耐熱ボトル
WO2003028664A2 (en) * 2001-10-03 2003-04-10 Teva Pharmaceutical Industries Ltd. Preparation of levofloxacin and forms thereof
EP1458391B1 (en) * 2001-11-30 2007-09-05 LG Life Sciences Ltd. A method of treating bacterial infections using gemifloxacin or a salt thereof and a beta-lactam antibiotic
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
WO2005000307A1 (en) * 2003-06-26 2005-01-06 Santen Pharmaceutical Co., Ltd. Ophthalmic composition containing quinolones and method of use
ES2671342T3 (es) * 2006-02-10 2018-06-06 Pari Pharma Gmbh Antibióticos nebulizados para terapia de inhalación
WO2008005276A2 (en) * 2006-06-30 2008-01-10 Directcontact Llc Growth factor delivery system containing antimicrobial agents
EP2143422A1 (en) * 2008-07-11 2010-01-13 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic compositions containing gemifloxacin for the treatment of ocular infections
PH12016501747B1 (en) * 2010-02-25 2022-06-22 Daiichi Sankyo Co Ltd Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof

Similar Documents

Publication Publication Date Title
JP2013241464A5 (https=)
Gebreyesus et al. Nasal and hand carriage rate of methicillin resistant Staphylococcus aureus (MRSA) among health care workers in Mekelle Hospital, North Ethiopia
PH12019500360A1 (en) Antibiotic compounds
WO2016049586A3 (en) Non-beta lactam antibiotics
PH12016502436A1 (en) Anti-infective compounds
Mirani et al. Small colony variants have a major role in stability and persistence of Staphylococcus aureus biofilms
MX2019003060A (es) Compuestos inhibidores de beta-lactamasa.
BR112017010132A2 (pt) terapia combinada para tratamento de infecções bacterianas resistentes
EA201691766A1 (ru) Органические соединения, являющиеся монобактамами, для лечения бактериальных инфекций
MY209256A (en) Compounds affecting pigment production and use thereof for treatment of bacterial diseases
JP2017519730A5 (https=)
PH12017500290B1 (en) Heterobicyclic compounds and their use for the treatment of tuberculosis
PH12019502509A1 (en) Compounds and methods for treating bacterial infections
WO2017218922A8 (en) Compositions and methods for the treatment of bacterial infections
CO2021015337A2 (es) Métodos y composiciones que comprenden variantes de la proteína a de estafilococos (spa)
WO2015024021A3 (en) Antibacterial compounds
WO2017137954A3 (en) Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
WO2013041663A3 (de) Modifizierte apidaecinderivate als antibiotische peptide
WO2015114452A3 (en) Antibacterial combinations comprising polymyxin
MX380076B (es) Inhibidores de beta-lactamasa.
EA201590876A1 (ru) Спироизоксазолиновые соединения, обладающие активностью, усиливающей активность антибиотика
MX373098B (es) Derivados de manosa para tratar infecciones bacterianas.
IN2014DE02523A (https=)
BR112017008101A2 (pt) composto, composição farmacêutica, métodos para inibir o dnae bacteriano e para tratar uma infecção, e, uso de um composto.
PL410757A1 (pl) Nowy szczep Lactobacillus plantarum PL3, jego metabolit oraz zastosowanie szczepu Lactobacillus plantarum PL3 i jego metabolitu